Diagnostics company Quotient Limited (NASDAQ:QTNT) reported on Tuesday the receipt of approval from the the Food and Drug Administration (US FDA) for commercialisation of seven new blood bank reagents including two market firsts, for the US.

The company is the first to market the US FDA approved monoclonal Anti-Fy[b] and monoclonal Anti-C[w]. Its new Anti-Fy[b] and Anti-C[w] antisera give robust reactions with significantly shorter incubation times, improving technologist efficiency and confidence while Anti-C and Anti-e complete its line of Rh antisera, said theVP US Commercial, Bill Brady.

In addition to four new monoclonal antisera, the company is adding three essential AHG products to its extensive line of reagent red cells, ABO/Rh reagents, antisera, QC, as well as specialty products, Brady added.

Anti-Human Globulin (AHG) is an essential tool for laboratories responsible for blood transfusion. ALBAclone® monoclonal antisera are used in the laboratory to detect the presence of specific antigens on patient and donor red blood cells.